Glenmark Pharma shares soar 8% on FDA clean report, Investec predicts 17% upside

September 23, 2024

The global brokerage firm said that it expects both earnings momentum and importantly cash flow generation to continue. Additionally, it sees Glenmark as more of an India / RoW play as these two contribute >70% of its EBITDA.

More To Explore

REITs are the new blue-chips for passive income seekers: Ajay Srivastava

Ajay Srivastava, CEO of Dimensions Corporate, advises against investing in traditional sectors like cement and steel, favoring innovative companies with unique infrastructure. He remains invested

May 23, 2025

Irrational exuberance is evident; stock-picking discipline is more critical than ever: Ajay Srivastava

Ajay Srivastava of Dimensions Corporate observes irrationality in the market. He notes high PE ratios for some companies. He suggests caution and stock-specific investing. Srivastava

May 23, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003